WO2012052594A3 - USE OF Dlk1 AS AN ANGIOGENESIS INHIBITOR - Google Patents

USE OF Dlk1 AS AN ANGIOGENESIS INHIBITOR Download PDF

Info

Publication number
WO2012052594A3
WO2012052594A3 PCT/ES2011/070728 ES2011070728W WO2012052594A3 WO 2012052594 A3 WO2012052594 A3 WO 2012052594A3 ES 2011070728 W ES2011070728 W ES 2011070728W WO 2012052594 A3 WO2012052594 A3 WO 2012052594A3
Authority
WO
WIPO (PCT)
Prior art keywords
dlk1
angiogenesis
expression
relates
angiogenesis inhibitor
Prior art date
Application number
PCT/ES2011/070728
Other languages
Spanish (es)
French (fr)
Other versions
WO2012052594A2 (en
Inventor
Santiago LAMAS PELÁEZ
Patricia RODRÍGUEZ PÉREZ
María Ángeles HIGUERAS LÓPEZ
Jorge LABORDA FERNÁNDEZ
Original Assignee
Consejo Superior De Investigaciones Científicas (Csic)
Universidad De Castilla La Mancha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investigaciones Científicas (Csic), Universidad De Castilla La Mancha filed Critical Consejo Superior De Investigaciones Científicas (Csic)
Publication of WO2012052594A2 publication Critical patent/WO2012052594A2/en
Publication of WO2012052594A3 publication Critical patent/WO2012052594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the use of a gene construction comprising a sequence encoding Dlk1 or the recombinant protein resulting from the expression of said gene construction for the preparation of a medicament for inhibiting angiogenesis, preferably tumoral angiogenesis. The invention also relates to the use of a product of the expression of Dlk1 or any of its fragments as a biomarker for determining angiogenesis or the progression thereof. The invention further relates to a method for determining pathological angiogenesis or the progression thereof, and to the use of a kit comprising the sequence encoding for dlk1 or any of its expression products for the diagnosis of pathological angiogenesis.
PCT/ES2011/070728 2010-10-21 2011-10-21 USE OF Dlk1 AS AN ANGIOGENESIS INHIBITOR WO2012052594A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031547A ES2381161B1 (en) 2010-10-21 2010-10-21 USE OF DLK1 AS AN ANGIOGENESIS INHIBITOR.
ESP201031547 2010-10-21

Publications (2)

Publication Number Publication Date
WO2012052594A2 WO2012052594A2 (en) 2012-04-26
WO2012052594A3 true WO2012052594A3 (en) 2014-12-04

Family

ID=45975665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070728 WO2012052594A2 (en) 2010-10-21 2011-10-21 USE OF Dlk1 AS AN ANGIOGENESIS INHIBITOR

Country Status (2)

Country Link
ES (1) ES2381161B1 (en)
WO (1) WO2012052594A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644031A (en) * 1992-12-11 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Delta-like gene expressed in neuroendocrine tumors
US20090326205A1 (en) * 2006-11-10 2009-12-31 Liv Tech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644031A (en) * 1992-12-11 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Delta-like gene expressed in neuroendocrine tumors
US20090326205A1 (en) * 2006-11-10 2009-12-31 Liv Tech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YEVTODIYENKO A. ET AL.: "Dlkl Expression Marks Developing Endothelium and Sites of Branching Morphogenesis in the Mouse Embryo and Placenta.", DEVELOPMENTAL DYNAMICS., vol. 235, 2006, pages 1115 - 1123 *
YIN D. ET AL.: "DLK1 increased expression in gliomas and associated with oncogenicActivities.", ONCOGENE, vol. 25, 2006, pages 1852 - 1861 *

Also Published As

Publication number Publication date
ES2381161B1 (en) 2013-04-18
ES2381161A1 (en) 2012-05-23
WO2012052594A2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
WO2013006953A8 (en) Genes and proteins for alkanoyl-coa synthesis
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
CA2865388C (en) Novel fgfr3 fusion
EP2351575A4 (en) Novel uses of grs proteins or fragments thereof
WO2012048340A3 (en) High-throughput immune sequencing
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
WO2008148068A8 (en) Multicistronic vectors and methods for their design
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2011130222A3 (en) Compositions and methods comprising variant proteases
WO2014005683A8 (en) Dna vaccine for use in pancreatic cancer patients
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
MY166157A (en) Antibodies to bradykinin b1 receptor ligands
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
EP2529033A4 (en) Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
WO2014036040A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2014058976A3 (en) Biomarkers predictive for clinical response for glatiramer acetate
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
WO2013072901A3 (en) Compositions and methods for treating glioma
WO2012136898A3 (en) Novel cutinases, their production and uses
WO2011100752A3 (en) Methods and materials for assessing rna expression
MX2015016114A (en) Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment.
MX364626B (en) Mimetic peptides.
WO2013093347A3 (en) A method for the in vitro diagnosis or prognosis of ovarian cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11833901

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11833901

Country of ref document: EP

Kind code of ref document: A2